FDA panel supports broader use of Medtronic heart devices


Oct 8 (Reuters) - A federal advisory panel recommended thatMedtronic Inc be allowed to sell certain implantableelectronic heart devices to a larger pool of patients, based onstudy results that showed the products reduced the risk of deathand hospitalization.

The panel of expert advisers to the U.S. Food and DrugAdministration voted 4-3 on Tuesday to recommend that Medtronicbe approved to sell the products, called cardiacresynchronization therapy devices, to patients who suffer froman abnormal heart rhythm called atrioventricular block.

The devices, also known as CRT-defibrillators andCRT-pacemakers, deliver electrical impulses to both lowerchambers of the heart to restore its normal rhythm.

View Comments